TY - JOUR T1 - No Survival Benefit from the Inhibition of Renin–Angiotensin System in Biliary Tract Cancer JF - Anticancer Research JO - Anticancer Res SP - 4965 LP - 4970 VL - 36 IS - 9 AU - YOUSUKE NAKAI AU - HIROYUKI ISAYAMA AU - TAKASHI SASAKI AU - NAMINATSU TAKAHARA AU - KEI SAITO AU - TSUYOSHI TAKEDA AU - GYOTANE UMEFUNE AU - TOMOTAKA SAITO AU - KAORU TAKAGI AU - TAKEO WATANABE AU - TSUYOSHI HAMADA AU - RIE UCHINO AU - SUGURU MIZUNO AU - KEISUKE YAMAMOTO AU - HIROFUMI KOGURE AU - SABURO MATSUBARA AU - NATSUYO YAMAMOTO AU - HIDEAKI IJICHI AU - KEISUKE TATEISHI AU - MINORU TADA AU - KAZUHIKO KOIKE Y1 - 2016/09/01 UR - http://ar.iiarjournals.org/content/36/9/4965.abstract N2 - Aim: The renin–angiotensin system (RAS) was investigated as a target for cancer treatment. Patients and Methods: A total of 287 patients with biliary tract cancer (BTC) receiving chemotherapy were retrospectively studied to evaluate the role of inhibition of RAS by angiotensin system inhibitors (ASIs). Progression-free survival (PFS) and overall survival (OS) were compared between 74 patients with hypertension, on ASIs (ASI group), 50 patients with hypertension not on ASIs (non-ASI with HT group) and 163 patients without hypertension (non-HT group). Interactions between the use of ASIs and various subgroups were explored. Results: The median PFS was 3.6, 3.9 and 4.6 months (p=0.495) and the median OS was 11.6, 10.9 and 13.1 months (p=0.668), respectively. The use of ASIs was not associated with OS (hazard ratio 1.00, p=0.975) and no subgroups with better survival were identified. Conclusion: No survival benefit from ASIs was observed in BTC. ER -